论文部分内容阅读
目的对药物瑞舒伐他汀、辛伐他汀用于高脂血症治疗的可行性、安全性情况进行观察分析。方法选取医院收治的高血脂症患者86例,随机分为观察1组和观察2组,每组43例。观察1组给予辛伐他汀进行降脂治疗,观察2组给予瑞舒伐他汀药物治疗,对2组患者降脂效果进行评估,同时对用药所致不良反应发生情况进行统计。结果观察2组降脂总有效率为88.37%,高于观察1组的74.42%(P<0.05);用药后,观察2组血脂指标改善效果优于观察1组(P<0.01);观察1组不良反应发生率为6.98%,观察2组不良反发生率为9.30%,2组比较差异无统计学意义(P>0.05)。结论临床上瑞舒伐他汀、辛伐他汀均能改善患者血脂情况,但前者降脂效果较好,改善血脂指标。
Objective To observe and analyze the feasibility and safety of drugs rosuvastatin and simvastatin in the treatment of hyperlipidemia. Methods Totally 86 patients with hyperlipidemia admitted to hospital were randomly divided into observation group 1 and observation group 2, with 43 cases in each group. One group was treated with simvastatin for lipid-lowering treatment. The two groups were given rosuvastatin drug treatment, the lipid-lowering effect was evaluated in two groups, and the incidence of adverse reactions caused by the drug was counted. Results The total effective rate of lipid lowering in the two groups was 88.37%, which was higher than 74.42% in the observation group 1 (P <0.05). After administration, the improvement of the blood lipid index in the two groups was better than that in the observation group 1 (P <0.01) The incidence of adverse reactions was 6.98%. The incidence of adverse reactions in the two groups was 9.30%. There was no significant difference between the two groups (P> 0.05). Conclusion Both rosuvastatin and simvastatin can improve the blood lipid level in patients, but the former has better lipid-lowering effect and improves the lipid level.